Alovudine

Alovudine
Clinical data

Identifiers
CAS Registry Number	25526-93-6^N
ATC code	None
PubChem	CID 33039
ChemSpider	30578^Y
UNII	PG53R0DWDQ^Y
KEGG	D02830^Y
ChEMBL	CHEMBL105318^Y
Chemical data
Formula	C₁₀H₁₃F₂N₂O₄
Molecular mass	244.22 g/mol
SMILES O=C/1NC(=O)N(\C=C\1C)[C@@H]2O[C@@H]([C@@H](F)C2)CO
InChI InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1 ^Y Key:UXCAQJAQSWSNPQ-XLPZGREQSA-N ^Y
N (what is this?) (verify)

Alovudine was an antiviral agent being developed by Medivir, which was discontinued after a Phase II trial in 2005 due to toxicity. It was a DNA polymerase inhibitor.^[1]

References

↑ Georgopapadakou N. Discontinued drugs in 2005: anti-infectives. Expert Opin Investig Drugs. 2007 Jan;16(1):1-10. PMID 17155849

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Entry/fusion inhibitors
(Discovery and development)

gp41 (Enfuvirtide (ENF, T-20))
CCR5 (Maraviroc (MVC)
Vicriviroc^†, Cenicriviroc^†, PRO 140^†)
CD4 (Ibalizumab^†)
gp120 (Fostemsavir^†)

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and nucleotide (NRTI)	Nucleoside analogues/NARTIs: Abacavir (ABC)°^# Emtricitabine (FTC)°^# Lamivudine (3TC)°^# Didanosine (ddI)^# Zidovudine (AZT, ZDV)^# Apricitabine^† Stampidine^† Elvucitabine^† Racivir^† Amdoxovir^† Stavudine (d4T)^# Zalcitabine (ddC)^◊ Festinavir^† Nucleotide analogues/NtRTIs: Tenofovir disoproxil fumarate (TDF)°^# Tenofovir alafenamide fumarate (TAF)^†

Non-nucleoside (NNRTI) (Discovery and development)	(1st generation) Efavirenz (EFV)°^# Nevirapine (NVP)^# Delavirdine (DLV)^◊ (2nd generation) diarylpyrimidines (Etravirine (ETR) Rilpivirine (RPV)°) Doravirine

Integrase inhibitors

Raltegravir (RAL)°
Elvitegravir (EVG)°
Dolutegravir (DTG)°
Globoidnan A (experimental)
MK-2048^†
BI 224436^†
Cabotegravir^†

Maturation inhibitors

Bevirimat^†

Protease Inhibitors (PI)
(Discovery and development)

1st generation	Fosamprenavir (FPV) Lopinavir (LPV)°^# Nelfinavir (NFV)^# Ritonavir (RTV)^# Saquinavir (SQV)^# Amprenavir (APV)^◊ Indinavir (IDV)^◊^# Telinavir Droxinavir

2nd generation	Atazanavir (ATV)° Darunavir (DRV)° Tipranavir (TPV)

Combined formulations

Lamivudine/zidovudine
Lopinavir/ritonavir°
Abacavir/lamivudine/zidovudine
Abacavir/lamivudine°
Tenofovir/emtricitabine°
Emtricitabine/tenofovir/efavirenz°
Emtricitabine/rilpivirine/tenofovir°
Elvitegravir/cobicistat/emtricitabine/tenofovir°
Abacavir/dolutegravir/lamivudine°
Atazanavir/cobicistat
Darunavir/cobicistat
Lamivudine/raltegravir

Boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)

Transcription inhibitors	Tat antagonists

Translation inhibitors	Trichosanthin

Other	Abzyme Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Griffithsin Hydroxycarbamide Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor KP-1461^† BIT225^†

Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Emivirine Lersivirine Lodenosine Loviride

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

Index of viral disease

Description	Virus classification Viral proteins

Disease	Systemic HIV and AIDS influenza Cutaneous Zoster Human papillomavirus Zoonotic Symptoms and signs

Treatment	Drugs antiretroviral DNA RNA Vaccines

DNA virus antivirals (primarily J05, also S01AD and D06BB)

Baltimore I

Herpesvirus

DNA-synthesis
inhibitor

TK activated

Purine analogue	guanine (Aciclovir^#/Valaciclovir Ganciclovir/Valganciclovir Penciclovir/Famciclovir) adenine (Vidarabine)

Pyrimidine analogue	uridine (Idoxuridine Trifluridine Edoxudine) thymine (Brivudine) cytosine (Cytarabine)

Not TK activated

Foscarnet

Other

HPV/MC

Vaccinia

assembly: Rifampicin

Poxviridae

Methisazone

Hepatitis B (VII)

Nucleoside analogues/NARTIs: Entecavir
Lamivudine
Telbivudine
Clevudine

Nucleotide analogues/NtRTIs: Adefovir
Tenofovir

Multiple/general

Nucleic acid inhibitors	Cidofovir

Interferon	Interferon alfa 2b Peginterferon alfa-2a

Multiple/unknown	Ribavirin^#/Taribavirin^† Moroxydine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Index of viral disease

Description	Virus classification Viral proteins

Disease	Systemic HIV and AIDS influenza Cutaneous Zoster Human papillomavirus Zoonotic Symptoms and signs

Treatment	Drugs antiretroviral DNA RNA Vaccines

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

protease inhibitors
- Asunaprevir^†
- Boceprevir
- Faldaprevir^†
- Grazoprevir^†
- Telaprevir
- Simeprevir
RNA polymerase inhibitors
- Sofosbuvir
NS5A inhibitors
- ACH-3102^†
- Daclatasvir
- Deleobuvir^§
- Elbasvir^†
- Ledipasvir
- MK-3682
- MK-8408
- Samatasvir

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

Arbidol

adamantane derivatives/M2 inhibitors (Amantadine
Rimantadine)

neuraminidase inhibitors/release phase (Oseltamivir
Zanamivir
Peramivir, Laninamivir^†)

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a

Multiple/unknown	BCX4430 Ribavirin^#/Taribavirin^† Moroxydine Favipiravir

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Index of viral disease

Description	Virus classification Viral proteins

Disease	Systemic HIV and AIDS influenza Cutaneous Zoster Human papillomavirus Zoonotic Symptoms and signs

Treatment	Drugs antiretroviral DNA RNA Vaccines